{
  "id": 10363009,
  "title": "IASO Bio achieves 95 9 percent response rate in FUCASO study",
  "url": "https://urgent.news/2026/09/28/iaso-bio-achieves-95-9-percent-response-rate-in-fucaso-study",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-28T04:36:28.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/iaso-bio-achieves-959-percent-response-rate-in-fucaso-study-161691.html"
  },
  "original_language": "en",
  "account": "Shanghai, Nanjing, China, and Pleasanton, California - September 27, 2026 - IASO Biotechnology, a biopharmaceutical company concentrating on novel cell therapies for hematologic malignancies and autoimmune diseases, unveiled results from a real-world study of its first fully human BCMA-targeting CAR-T cell therapy, FUCASO, at the 2026 International Myeloma Society Annual Meeting. The study, comprising 281 patients, showcased an impressive 95.9% objective response rate and a 77.2% complete response or stringent complete response rate. Although median progression-free and overall survival rates were not yet achieved at 10.97 months, the 12-month progression-free and overall survival rates stood at 71.5% and 87.8%, respectively.",
  "summary": "Biopharmaceutical firm IASO Bio presented clinical trial results showing a 95 9 percent objective response rate for its FUCASO therapy in patients with relapsed plasma cell neoplasms",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Vietnam Investment Review",
        "title": "IASO Bio reports 90 percent response rate for CAR T therapy",
        "url": "https://urgent.news/2026/09/28/iaso-bio-reports-90-percent-response-rate-for-car-t-therapy",
        "published": "2026-09-28T04:41:20.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}